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Summary
Background Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects 
on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to 
determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. 
Methods We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly 
assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that 
either received a subcutaneous injection of albiglutide (30–50 mg, based on glycaemic response and tolerability) or of 
a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or 
web response system to obtain treatment assignment, and patients and all study investigators were masked to their 
treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of 
the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-
treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, 
closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515.
Findings Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 
9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide 
and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median 
follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study 
treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were 
evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite 
outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide 
group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group 
(hazard ratio 0·78, 95% CI 0·68–0·90), which indicated that albiglutide was superior to placebo (p<0·0001 for non-
inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and 
seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the 
placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not 
differ between the two groups. There were three (<1%) deaths in the placebo group that were assessed by investigators, 
who were masked to study drug assignment, to be treatment-related and two (<1%) deaths in the albiglutide group.
Interpretation In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with 
respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should 
therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients 
with type 2 diabetes.
Funding GlaxoSmithKline.
Copyright © 2018 Elsevier Ltd. All rights reserved.
Introduction
The risk of fatal and non-fatal cardiovascular events is 
much higher in people with type 2 diabetes than in the 
general population.1,2 Drugs in two classes of newer 
glucose-lowering therapies, the sodium-glucose co-
transporter 2 (SGLT-2) inhibitors and the glucagon-like 
peptide 1 (GLP-1) receptor agonists, have been shown to 
reduce the risk of major adverse cardiovascular events, 
although findings regarding the GLP-1 receptor agonists 
have been inconsistent.3–8 Specifically, not all tested 
GLP-1 receptor agonists have been shown to reduce 
cardiovascular events, and the effect of these treatments 
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on individual cardiovascular outcomes varied between 
the effective drugs.5–8 Liraglutide and semaglutide, which 
have structural homology to native GLP-1, reduced 
cardiovascular events, whereas no benefit was associated 
with the exendin-4 based drugs lixisenatide and 
exenatide.5–8 In addition to differences in chemical 
structure and potency, these treatments also differ 
markedly in duration of action and were studied in 
different patient populations and in trials of different 
design, size, and duration of follow-up.5–8 Consequently, 
uncertainty remains about the cardiovascular effects of 
GLP-1 receptor agonists.
Albiglutide is a GLP-1 receptor agonist that is generated 
through genetic fusion of two tandem copies of modified 
human GLP-1 (with 97% aminoacid sequence homology 
to endogenous human GLP-1 fragment 7–36) to human 
albumin, and the resultant protein is sufficiently long-
acting to be injected weekly.9,10 In accordance with 
regulatory guidance, we aimed to assess the cardio-
vascular safety and efficacy of albiglutide in Harmony 
Outcomes, a trial that enrolled patients with type 2 
diabetes and cardiovascular disease.11
Methods
Study design and participants
We did a double-blind, randomised, placebo-controlled, 
event-driven trial at 610 health-care sites in 28 countries 
across North and South America, Europe, Africa, and 
Asia.11 Men and women aged 40 years or older 
with a diagnosis of type 2 diabetes and established 
disease of the coronary (myocardial infarction, at least 
50% stenosis in one coronary artery or more, or previous 
coronary revascularisation), cerebrovascular (ischaemic 
stroke, at least 50% carotid artery stenosis, or a previous 
carotid vascular procedure), or peripheral arterial 
circulation (intermittent claudication and an ankle to 
brachial index <0·9, non-traumatic amputation, or a 
previous peripheral vascular procedure) who had a 
glycated haemoglobin concentration of more than 7·0% 
(53 mmol per mole) were eligible for participation 
in the trial.
Key exclusion criteria were an estimated glomerular 
filtration rate (eGFR) of less than 30 mL/min per 1·73 m², 
severe gastroparesis, previous pancreatitis or substantial 
risk factors for pancreatitis, a personal or family history of 
Research in context
Evidence before this study
We searched PubMed for reports of randomised trials that 
assessed the effects of glucagon-like peptide 1 (GLP-1) receptor 
agonists on cardiovascular outcomes. We searched for studies 
that were published in English up to Aug 1, 2018, with the 
search terms “glucagon-like peptide 1 agonist OR analogue”, 
“GLP-1 receptor agonist OR analogue”, “exenatide”, 
“lixisenatide”, “semaglutide”, “liraglutide”, “exenatide”, 
“dulaglutide”, “taspoglutide”, “albiglutide”, “cardiovascular 
outcomes”, and “diabetes”. Four trials with cardiovascular 
outcomes were identified. The LEADER trial included 
9340 patients with type 2 diabetes and cardiovascular disease 
or cardiovascular risk factors, who were followed up for a 
median duration of 3·8 years. Patients were randomly assigned 
to receive placebo or once-daily liraglutide, which is structurally 
homologous to native GLP-1, and this drug was added to 
standard care. Liraglutide reduced the frequency of the primary 
endpoint composite of major adverse cardiovascular events 
(MACE), which comprised cardiovascular death, myocardial 
infarction, and stroke, relative to the control group (hazard 
ratio 0·87, 95% CI 0·78–0·97; p<0·001 for non-inferiority; 
p=0·01 for superiority). Semaglutide, which is also structurally 
homologous to native GLP-1, was studied in 3297 similar 
participants in the SUSTAIN-6 trial, which showed, over a 
median duration of 2·1 years, that once-weekly semaglutide 
was non-inferior to placebo for MACE (0·74, 0·58–0·95; 
p<0·001 for non-inferiority). The ELIXA trial included 
6068 patients with type 2 diabetes and a recent acute coronary 
syndrome, who were followed up for a median duration of 
2·1 years. Patients were randomly assigned to receive placebo or 
once-daily lixisenatide, an exendin-4 based GLP-1 receptor 
agonist, which was added to standard care. Lixisenatide was 
non-inferior to placebo for the primary composite outcome of 
MACE plus unstable angina (1·02, 0·89–1·17; p<0·001 for 
non-inferiority). The EXSCEL trial included 14 752 patients with 
type 2 diabetes and cardiovascular disease or cardiovascular risk 
factors, who were followed up for a median duration of 
3·2 years. Patients were randomly assigned to receive placebo 
or once-weekly exenatide, which is an exendin-4 based GLP-1 
receptor agonist, which was added to standard care. Exenatide 
was non-inferior to placebo for the primary composite 
outcome of MACE (0·91, 0·83–1·00; p<0·001 for non-
inferiority; p=0·06 for superiority). There seems to be variation 
in the results of previous trials with GLP-1 receptor agonists 
that, if correct, might reflect drug structure or duration of 
action, patients studied, duration of follow-up, or other factors.
Added value of this study
The results of the Harmony Outcomes trial showed that 
albiglutide, a GLP-1 receptor ligand that is structurally 
homologous with native GLP-1, when administered 
once-weekly over a median duration of 1·6 years, reduced the 
risk of MACE when added to standard care in patients with 
type 2 diabetes and cardiovascular disease. These data suggest 
that certain GLP-1 receptor agonists reduce the risk of 
atherothrombotic events in patients with type 2 diabetes and 
high cardiovascular risk.
Implications of all the available evidence
Evidence-based GLP-1 receptor agonists should therefore be 
considered as part of a comprehensive strategy to reduce the risk 
of cardiovascular events, the leading cause of death and disability 
in patients with type 2 diabetes. 
Articles
www.thelancet.com   Published online October 2, 2018   http://dx.doi.org/10.1016/S0140-6736(18)32261-X 3
medullary carcinoma of the thyroid or multiple endocrine 
neoplasia type 2, a history of pancreatic neuroendocrine 
tumours, or current use of a GLP-1 receptor agonist. A 
complete list of trial inclusion and exclusion criteria is 
provided in the protocol (appendix 2). 
The protocol was approved by the ethics committee at 
each participating site and all patients provided written 
informed consent. An independent data and safety 
monitoring committee, with access to unblinded data, 
performed regular safety surveillance.
Randomisation and masking
Patients were assigned in a 1:1 ratio to receive 
subcutaneous injections of albiglutide or placebo (with 
matched administration device, diluent, and volume 
injected) once a week, according to a sequestered, fixed, 
computer-generated randomisation code that used 
balanced permuted blocks of treatment group allocations, 
without stratification. Investigators used an interactive 
voice or web response system to obtain treatment 
assignment. All investigators and patients involved in 
the trial were masked to treatment group.
Procedures
The starting dose of study medication was 30 mg in 
0·5 mL once a week. If, after at least 5 weeks of study 
treatment, the investigator determined that a trial 
participant required intensification of glucose-lowering 
therapy, the dose of study treatment could be increased 
to 50 mg; the dose could be decreased back to 30 mg if 
50 mg was not tolerated. If the glycaemic goal (which 
was based on local guidelines), as determined by the 
investigator, was not met after an increase in the dose 
of the study medication, other glucose-lowering 
medications could be adjusted or added (except for a 
GLP-1-receptor agonist). Protocol-specified reasons for 
discontinuation of trial medication included occurrence 
of pancreatitis, pancreatic cancer, medullary carcinoma 
of the thyroid or thyroid C-cell neoplasia, severe hyper-
sensitivity reactions that were attributable to study 
medication, pregnancy, an eGFR of less than 15 mL/min 
per 1·73 m², kidney dialysis or transplantation, or liver 
chemistry abnormalities that exceeded protocol-
specified thresholds.11 Patients had study visits every 4 
months, but endpoints were reported at the time of 
their occurrence. The number of visits was dependent 
on duration of involvement in the study; the 
assessments given at each visit are described in the 
protocol (appendix 2).
Outcomes
The primary outcome was the first occurrence of any 
component of the composite outcome, which comprised 
death from cardiovascular causes, myocardial infarction, 
and stroke, in an intention-to-treat population. Par-
ticipants were assessed until their last study visit, 
withdrawal from the study, being lost to follow-up, or 
their death. The secondary cardiovascular outcomes 
were a four-component composite (the primary com-
posite, with the addition of urgent revascularisation for 
unstable angina), the individual components of the 
primary endpoint, and the composite of cardiovascular 
death or hospital admission because of heart failure. 
The secondary metabolic outcomes were the time to 
initiation of chronic insulin therapy, the time to the 
first occurrence of an important microvascular event, 
changes in glycated haemoglobin and bodyweight, and 
the proportion of participants who attained glycaemic 
control without severe hypoglycaemia and who gained 
less than 5% of their bodyweight by the end of the study. 
The safety outcomes were the change in blood pressure 
and heart rate, change in eGFR, and adverse events of 
special interest, which included the development of 
prespecified malignancies (medullary thyroid cancer, 
pancreatic cancer, and haematological malignancies), 
pancreatitis, severe hypoglycaemia, injection site reac-
tions, immuno logical reactions, diabetic retino pathy, 
worsening renal function, and death from any cause. 
A complete list of endpoints is included in the proto col 
(appendix 2). An independent clinical events classi-
fication committee, whose members were unaware of 
the trial group assignments, assessed all the components 
of the primary composite outcome, secondary cardio-
vascular outcomes, and death; these events are defined 
in the clinical event definitions (appendix 1). A separate 
expert committee evaluated suspected cases of 
pancreatitis.
Statistical analysis
We aimed to investigate the effect of albiglutide compared 
with placebo on the primary outcome; we first aimed to 
test for non-inferiority and, if the prespecified criterion 
for non-inferiority was met, then for superiority. We used 
a closed testing procedure and so no adjustment of the 
significance level was required for testing of superiority.12 
Consistent with regulatory guidance, non-inferiority 
would be declared if the upper limit of the two-sided 
95% CI of the hazard ratio (HR) was less than 1·30, and 
superiority would be established if the upper limit was 
less than 1·00.13,14
Assuming a true hazard of 1·00, we estimated that 
611 events would be needed to have 90% power for the 
test of non-inferiority. An event rate in the range of 
2·0–3·0% per year was estimated for the primary 
endpoint, based on the results of previous trials,2,3 
meaning that the target of 611 events could be attained 
by assessing approximately 9400 patients for an average 
of 2·2–3·2 years. After the trial began, the masked 
aggregate event rate was observed to be higher than 
anticipated and, therefore, accrual of 611 events would 
occur over a much shorter period (potentially as short as 
a median duration of 1·1 years). To ensure adequate 
exposure for evaluation of safety, the protocol was 
revised on April 4, 2017, to require follow-up for a 
See Online for appendix 2
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median duration of at least 1·5 years in addition to the 
occurrence of at least 611 primary events.
The time-to-event analyses of the primary and secondary 
cardiovascular outcomes were assessed in the intention-
to-treat population by use of Cox proportional hazards 
regression, with treatment group as the only explanatory 
variable.15 The Kaplan-Meier method was used to estimate 
event rates. These analyses included all patients who had 
been randomly assigned to study treatment, whether this 
treatment had been taken or not, until the study closure 
visit (or the final date that vital status could be ascertained). 
No adjustment for multiplicity was prespecified for the 
secondary and other endpoints and only 95% CIs and 
nominal p values are provided.12
Figure 1: Trial profile
With regard to cardiovascular outcomes, 98·5% of the total possible follow-up time was attained in the albiglutide group, and 97·9% of the total possible follow-up 
time was attained in the placebo group. With regard to vital status endpoints, 99·8% of the total possible follow-up time was attained in both groups.
4732 assigned to receive placebo and included in 
the primary analysis
4715 received placebo
17 did not receive placebo
154 withdrew from the study
74 withdrew consent
68 lost to follow-up
8 physician decision
4 investigator site closed
111 withdrew from the study
43 withdrew consent
51 lost to follow-up
12 physician decision
5 investigator site closed
4578 completed the study4620 completed the study
1318 discontinued placebo before 
the end of the study
307 with adverse events
81 with disease-related events
63 protocol deviations
18 met protocol stopping 
criteria
56 lost to follow-up
786 decision by participant or 
proxy
7 investigator site closed
3397 were taking placebo at the end of the study
4577 had a complete
assessment of cardiovascular 
events at the end of the study
155 had incomplete assessment
at end of the study
4701 had known vital status at the
 end of the study
4496 alive
205 dead
31 unknown vital status
4619 had a complete assessment 
of cardiovascular events at 
the end of the study
112 had incomplete assessment 
at end of the study
4701 had known vital status at 
the end of the study
4505 alive
196 dead
30 unknown vital status
3556 were taking albiglutide at the end of the study
1161 discontinued albiglutide before 
the end of the study 
409 with adverse events
103 with disease-related events
28 protocol deviations
11 met protocol stopping 
criteria 
45 lost to follow-up
558 decision by participant or 
proxy
7 investigator site closed
4731 assigned to receive albiglutide and included in 
the primary analysis
4717 received albiglutide 
14 did not receive albiglutide
9463 randomised and included in the 
intention-to-treat population
10 793 screened
1330 not randomised
1040 did not meet inclusion criteria or met 
exclusion criteria
198 withdrew consent
30 lost to follow-up
49 physician decision
12 participant number already met
1 adverse event
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The primary composite outcome was analysed in 
prespecified subgroups that were defined by baseline 
characteristics, including age at randomisation; sex; race 
or ethnicity; geographic region; type of glucose-lowering 
therapy (insulin, metformin, and dipeptidyl peptidase-4 
inhibitor); duration of diabetes; history or no history of 
coronary artery disease, cerebrovascular disease, or 
peripheral arterial disease, and combinations of these; 
history or no history of heart failure; use of statin or 
antiplatelet therapy; history of smoking; body-mass index; 
glycated haemoglobin concentration; and eGFR. The 
safety analyses were done in all patients who were 
randomly assigned to groups and who received at least 
one dose of albiglutide or placebo.
Baseline characteristics were summarised as means 
with SDs, medians with IQRs, or percentages. 
Longitudinal measures, such as glycated haemoglobin 
concentration and bodyweight, were analysed with a 
mixed model for repeated measurements, and the least-
squares mean differences between treatment groups 
were estimated, together with 95% CIs. Analyses were 
done with SAS software, version 9.4 (SAS Institute).
Role of the funding source
The trial protocol was developed by the members of the 
Executive Committee in conjunction with Duke Clinical 
Research Institute and the sponsor, GlaxoSmithKline 
Research and Development. These parties were also re-
sponsible for oversight of the trial. The funder of the study 
was involved in data collection, data analysis, and data 
interpretation. The funder of the study was not involved in 
the writing of the report. The corresponding author had 
full access to all the data in the study and had final 
responsibility for the decision to submit for publication.
Results
Between July 1, 2015, and Nov 24, 2016, 10 793 patients 
were screened. On or before Dec 7, 2016, 9463 patients 
Albiglutide 
(n=4731)
Placebo 
(n=4732)
Age, years 64·1 (8·7) 64·2 (8·7)
Sex
Female 1427 (30%) 1467 (31%)
Male 3304 (70%) 3265 (69%)
Race or ethnicity
Non-Hispanic white 3295 (70%) 3288 (69%)
Asian 228 (5%) 242 (5%)
Non-Hispanic black or African-American 111 (2%) 114 (2%)
Hispanic 1005 (21%) 988 (21%)
Other 92 (2%) 100 (2%)
Geographic region
Western Europe 1684 (36%) 1708 (36%)
Eastern and central Europe 1037 (22%) 1010 (21%)
North America 967 (20%) 978 (21%)
Latin America 858 (18%) 845 (18%)
Asia Pacific 185 (4%) 191 (4%)
Current smokers 737 (16%) 751 (16%)
Medical history
Coronary artery disease* 3333 (70%) 3345 (71%)
Hypertension 4089 (86%) 4095 (87%)
Myocardial infarction 2223 (47%) 2236 (47%)
Coronary artery bypass surgery 890 (19%) 842 (18%)
Percutaneous coronary intervention 2050 (43%) 2113 (45%)
Stroke 827 (17%) 854 (18%)
Peripheral artery disease 1195 (25%) 1159 (24%)
Heart failure 954 (20%) 968 (20%)
Atrial fibrillation 394 (8%) 392 (8%)
Body-mass index, kg/m² 32·3 (5·9) 32·3 (5·9)
Blood pressure, mm Hg
Systolic 134·8 (16·6) 134·7 (16·5)
Diastolic 76·8 (10·1) 76·8 (10·1)
Glycated haemoglobin, % 8·76 (1·5) 8·72 (1·5)
eGFR, mL/min per 1·73 m² 79·1 (25·6) 78·9 (25·4)
(Table 1 continues in next column)
Albiglutide 
(n=4731)
Placebo 
(n=4732)
(Continued from previous column)
Duration of diabetes, years 14·1 (8·6) 14·2 (8·9)
History of microvascular disease
Diabetic eye disease 982 (21%) 955 (20%)
Nephropathy 898 (19%) 840 (18%)
Peripheral sensory neuropathy 1562 (33%) 1533 (32%)
Autonomic neuropathy 143 (3%) 107 (2%)
Cardiovascular medications
Beta-blocker 3128 (66%) 3182 (67%)
Calcium channel blocker 1428 (30%) 1431 (30%)
Angiotensin-converting-enzyme inhibitor 2263 (48%) 2353 (50%)
Angiotensin receptor blocker 1599 (34%) 1511 (32%)
Thiazide diuretic 1089 (23%) 1037 (22%)
Loop diuretic 895 (19%) 899 (19%)
Statin 3967 (84%) 3988 (84%)
Aspirin 3652 (77%) 3639 (77%)
P2Y12 inhibitor 1224 (26%) 1251 (26%)
Glucose-lowering medications
None or diet 42 (1%) 35 (1%)
Biguanide 3463 (73%) 3506 (74%)
Sulfonylurea 1346 (28%) 1379 (29%)
Insulin 2860 (60%) 2737 (58%)
Dipeptidyl peptidase 4 inhibitor 698 (15%) 739 (16%)
Sodium-glucose cotransporter 
2 inhibitor
310 (7%) 265 (6%)
Thiazolidinedione 92 (2%) 102 (2%)
Glinide 66 (1%) 96 (2%)
α-glucosidase inhibitor 34 (1%) 37 (1%)
Data are mean (SD) or number (%). *Any of myocardial infarction, coronary artery 
bypass grafting, percutaneous coronary intervention, or at least 50% stenosis of 
coronary artery on angiography. eGFR=estimated glomerular filtration rate.
Table 1: Characteristics of the patients at baseline
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Albiglutide (n=4731) Placebo (n=4732) Hazard ratio (95% CI) p value*
Number of 
patients (%)
Incidence rate 
(number of events 
per 100 person-years)
Number of 
patients (%)
Incidence rate 
(number of events 
per 100 person-years)
Primary composite outcome† 338 (7%) 4·57 428 (9%) 5·87 0·78 (0·68–0·90) <0·0001, 0·0006
Secondary outcomes
Expanded composite outcome‡ 373 (8%) 5·06 468 (10%) 6·45 0·78 (0·69–0·90) 0·0005
Death from cardiovascular causes 122 (3%) 1·61 130 (3%) 1·72 0·93 (0·73–1·19) 0·578
Fatal or non-fatal myocardial infarction 181 (4%) 2·43 240 (5%) 3·26 0·75 (0·61–0·90) 0·003
Fatal or non-fatal stroke 94 (2%) 1·25 108 (2%) 1·45 0·86 (0·66–1·14) 0·300
Composite of death from cardiovascular 
causes or hospital admission for heart failure
188 (4%) 2·49 218 (5%) 2·92 0·85 (0·70–1·04) 0·113
Death from any cause 196 (4%) 2·44 205 (4%) 2·56 0·95 (0·79–1·16) 0·644
Hazard ratios and p values were estimated with a Cox proportional hazards model with treatment as the sole explanatory variable. *Data for the primary outcome are the p value for non-inferiority, p value for 
superiority; all other p values are nominal p values for superiority. †Included death from cardiovascular causes (102 patients in the albiglutide group vs 109 patients in the placebo group), non-fatal myocardial 
infarction (160 patients vs 228 patients), or non-fatal stroke (76 patients vs 91 patients). ‡Included death from cardiovascular causes, non-fatal myocardial infarction, non-fatal stroke, or urgent coronary 
revascularisation for unstable angina.
Table 2: Primary and secondary cardiovascular outcomes
Figure 2: Kaplan-Meier plot of time to first occurrence of major adverse cardiovascular events
Data are (A) the primary outcome, which was a composite of death from cardiovascular causes, myocardial infarction, or stroke; and each of these components 
individually: (B) cardiovascular death, (C) myocardial infarction, and (D) stroke. Analyses are of all participants who were randomly assigned to groups. The graphs are 
truncated at the point at which less than 10% of patients remain at risk. HR=hazard ratio.
A
Number at risk
Albiglutide
Placebo
0
4731
4732
4
4613
4603
8
4503
4460
12
4239
4208
16
3148
3074
20
2142
2077
24
1064
1030
28 0 4 8 12 16 20 24 28
0 4 8 12 16 20 24 28 0 4 8 12 16 20 24 28
..
..
0
2
4
6
8
12
14
10
16
Cu
m
ul
at
iv
e 
pe
rc
en
ta
ge
 w
ith
 a
n 
ev
en
t (
%
) Albiglutide (338 events)
Placebo (428 events)
B
4731
4732
4681
4662
4611
4580
4379
4373
3274
3245
2234
2226
1121
1121
..
..
Albiglutide (122 events)
Placebo (130 events)
C
Number at risk
Albiglutide
Placebo
4731
4732
4635
4624
4543
4496
4286
4262
3184
3124
2167
2122
1080
1056
..
..
Time since randomisation (months)
0
2
4
6
8
12
14
10
16
Cu
m
ul
at
iv
e 
pe
rc
en
ta
ge
 w
ith
 a
n 
ev
en
t (
%
) Albiglutide (181 events)
Placebo (240 events)
D
4731
4732
4658
4640
4570
4543
4328
4318
3233
3194
2205
2178
1103
1093
..
..
Time since randomisation (months)
Albiglutide (94 events)
Placebo (108 events)
HR=0·78; 95% CI 0·68–0·90
Non-inferiority p value <0·0001
Superiority p value=0·0006
HR=0·93; 95% CI 0·73–1·19
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Primary analysis
Sex
Female
Male
Race or ethnicity
Non-Hispanic white
Non-Hispanic black
Hispanic
Asian
Other
Age
<65 years
≥65 to <75 years
≥75 years
Region
North America
Latin America
Asia Pacific
Eastern Europe
Western Europe
Coronary artery disease
Yes
No
Cerebrovascular disease
Yes
No
Peripheral arterial disease
Yes
No
Number of arterial beds involved
1
2 or 3
Heart failure history
Yes
No
Smoking history
Current
Former
Never
Baseline eGFR (mL/min per 1·73 m2)
<60
≥60 to <90
≥90
Baseline BMI (kg/m2)
<30
≥30
Duration of diabetes
< 10 years
≥10 years to <20 years
≥20 years
Baseline HbA1c
<8·0%
≥8·0% to <9·0%
≥9·0%
Baseline insulin
Yes
No
Baseline metformin
Yes
No
Baseline dipeptidyl peptidase 4
Yes
No
Baseline statin
Yes
No
Baseline antiplatelet
Yes
No
Number of 
patients
9463
2894
6569
6583
225
1993
470
192
4714
3609
1140
1945
1703
376
2047
3392
6678
2785
2342
7121
2354
7109
7702
1742
1922
7541
1488
4082
3891
2222
4417
2824
3613
5800
3355
3925
2167
3524
2691
3248
5597
3866
6968
2495
1437
8026
7955
1503
7959
1499
Albiglutide 
Events/patients (%)
 338/4731 (7·1%)
 79/1427 (5·5%)
 259/3304 (7·8%)
 248/3295 (7·5%)
 19/111 (17·1%)
 51/1005 (5·1%)
 13/228 (5·7%)
 7/92 (7·6%)
 134/2385 (5·6%)
 154/1771 (8·7%)
 50/575 (8·7%)
 107/967 (11·1%)
 39/858 (4·5%)
 8/185 (4·3%)
 64/1037 (6·2%)
 120/1684 (7·1%)
 285/3333 (8·6%)
 53/1398 (3·8%)
 100/1171 (8·5%)
 238/3560 (6·7%)
 106/1195 (8·9%)
 232/3536 (6·6%)
 209/3846 (5·4%)
 129/877 (14·7%)
 101/954 (10·6%)
 237/3777 (6·3%)
 72/737 (9·8%)
 159/2083 (7·6%)
 107/1910 (5·6%)
 116/1098 (10·6%)
 144/2208 (6·5%)
 78/1425 (5·5%)
 116/1788 (6·5%)
 219/2914 (7·5%)
 91/1660 (5·5%)
 146/1987 (7·3%)
 98/1072 (9·1%)
 113/1749 (6·5%)
 88/1312 (6·7%)
 137/1670 (8·2%)
 243/2860 (8·5%)
 95/1871 (5·1%)
 220/3462 (6·4%)
 118/1269 (9·3%)
 55/698 (7·9%)
 283/4033 (7·0%)
 283/3967 (7·1%)
 55/760 (7·2%)
 282/3971 (7·1%)
 56/756 (7·4%)
 428/4732 (9·0%)
 120/1467 (8·2%)
 308/3265 (9·4%)
 323/3288 (9·8%)
 8/114 (7·0%)
 65/988 (6·6%)
 19/242 (7·9%)
 13/100 (13·0%)
 193/2329 (8·3%)
 166/1838 (9·0%)
 69/565 (12·2%)
 118/978 (12·1%)
 49/845 (5·8%)
 12/191 (6·3%)
 89/1010 (8·8%)
 160/1708 (9·4%)
 340/3345 (10·2%)
 88/1387 (6·3%)
 124/1171 (10·6%)
 304/3561 (8·5%)
 107/1159 (9·2%)
 321/3573 (9·0%)
 301/3856 (7·8%)
 127/865 (14·7%)
 146/968 (15·1%)
 282/3764 (7·5%)
 63/751 (8·4%)
 210/1999 (10·5%)
 155/1981 (7·8%)
 128/1124 (11·4%)
 206/2209 (9·3%)
 94/1399 (6·7%)
 164/1825 (9·0%)
 262/2886 (9·1%)
 138/1695 (8·1%)
 178/1938 (9·2%)
 112/1095 (10·2%)
 121/1775 (6·8%)
 133/1379 (9·6%)
 174/1578 (11·0%)
 270/2737 (9·9%)
 158/1995 (7·9%)
 281/3506 (8·0%)
 147/1226 (12·0%)
 57/739 (7·7%)
 371/3993 (9·3%)
 362/3988 (9·1%)
 66/743 (8·9%)
 360/3988 (9·0%)
 68/743 (9·1%)
Placebo
Events/patients (%)
Hazard ratio
0·78 (0·68–0·90)
0·67 (0·50–0·89)
0·82 (0·69–0·97)
0·76 (0·64–0·89)
2·60 (1·14–5·94)
0·74 (0·52–1·07)
0·73 (0·36–1·48)
0·56 (0·23–1·41)
0·66 (0·53–0·82)
0·97 (0·78–1·21)
0·69 (0·48–1·00)
0·92 (0·70–1·19)
0·76 (0·50–1·16)
0·69 (0·28–1·69)
0·68 (0·50–0·94)
0·76 (0·60–0·96)
0·83 (0·71–0·97)
0·59 (0·42–0·82)
0·80 (0·61–1·04)
0·77 (0·65–0·91)
0·96 (0·73–1·25)
0·72 (0·61–0·85)
0·68 (0·57–0·81)
1·02 (0·80–1·30)
0·70 (0·54–0·90)
0·82 (0·69–0·98)
1·16 (0·82–1·62)
0·71 (0·58–0·88)
0·71 (0·55–0·91)
0·93 (0·73–1·20)
0·69 (0·56–0·85)
0·79 (0·59–1·07)
0·72 (0·57–0·91)
0·81 (0·68–0·97)
0·67 (0·51–0·87)
0·78 (0·63–0·97)
0·90 (0·68–1·17)
0·94 (0·73–1·22)
0·68 (0·52–0·89)
0·73 (0·58–0·91)
0·85 (0·72–1·01)
0·63 (0·49–0·81)
0·77 (0·65–0·92)
0·79 (0·62–1·00)
1·04 (0·72–1·50)
0·74 (0·63–0·86)
0·78 (0·66–0·91)
0·80 (0·56–1·14)
0·77 (0·66–0·90)
0·80 (0·56–1·14)
Hazard ratio
(95% CI)
0·227
0·065
0·037
0·691
0·066
0·835
0·077
0·010
0·278
0·038
0·186
0·435
0·308
0·187
0·053
0·928
0·100
0·899
0·852
pinteraction
Favours albiglutide Favours placebo
0·25 0·5 1·0 2·0 4·0 8·0
Figure 3: Primary composite 
outcome in prespecified 
subgroups
Patients self-reported their 
race or ethnicity. 
Cerebrovascular disease 
included any of stroke, at least 
50% carotid artery stenosis, or 
a previous carotid arterial 
procedure. p values for 
homogeneity for 
between-group differences 
were obtained by fitting 
interaction terms, with no 
adjustment for multiple 
testing. eGFR=estimated 
glomerular filtration rate. 
BMI=body-mass index. 
HbA1c=glycated haemoglobin.
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were randomly assigned to groups (4731 patients in the 
albiglutide group and 4732 patients in the placebo group) 
and formed the intention-to-treat population who were 
included in the analysis of the primary outcome (figure 1). 
1330 patients were excluded, of whom the majority 
(1040 [78%] patients) did not meet inclusion criteria or 
met exclusion criteria.
The demographic and clinical characteristics of the 
patients were similar between the two groups (table 1). The 
mean age of the participants was 64·1 years and 31% were 
women. The mean duration of diabetes was 14·1 years, the 
mean eGFR was 79 mL/min per 1·73 m², and the mean 
glycated haemoglobin concen tration was 8·7% (SD 1·5). 
Among the participants, 6678 (71%) par ticipants had a 
history of coronary artery disease, 2354 (25%) had 
peripheral artery disease, 2342 (25%) had cerebrovascular 
disease and 1922 (20%) had a history of heart failure. 
Patients received standard therapies for diabetes and 
cardiovascular disease.
From Nov 8, 2017, when it was projected that 
611 primary endpoints and a median follow-up of at least 
1·5 years had accrued, subjects returned for a final visit 
and discontinuation from study treatment, with the last 
patient study visit on March 12, 2018. The actual median 
duration of follow-up was 1·6 years (IQR 1·3–2·0; 
maximum 2·6) for the primary outcome. Vital status was 
not known for 61 (0·6%) of 9463 participants, which 
included 30 patients from the albiglutide group and 
31 patients from the placebo group (figure 1). 1140 (24%) of 
4731 patients assigned to receive albiglutide and 
1297 (27%) of 4732 patients assigned to receive placebo 
discontinued study medication prematurely for reasons 
other than death. Study treatment was taken for 87% of 
the total follow-up time for cardiovascular outcomes in 
the albiglutide group and 85% of that time in the placebo 
group. Among patients who received at least one dose of 
albiglutide or placebo, 2371 (50%) of 4717 patients in the 
albiglutide group were taking the maximum dose of 
50 mg at the time of their last recorded dose, and 
2982 (63%) of 4715 patients in the placebo group were 
taking the volume-matched equivalent.
The primary composite endpoint occurred in 
338 (7%) of 4731 patients at an event rate of 4·57 events 
per 100 person-years in the albiglutide group and in 
428 (9%) of 4732 patients at an event rate of 5·87 events 
per 100 person-years in the placebo group (HR 0·78, 
Figure 4: Effects of once-weekly albiglutide
Data are the effects of once-weekly administration of albiglutide on (A) glycated haemoglobin concentration, (B) bodyweight, (C) systolic blood pressure, 
and (D) estimated glomerular filtration rate.
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95% CI 0·68–0·90), indicating that albiglutide was 
both non-inferior to placebo for cardiovascular safety 
(p<0·0001 for non-inferiority) and superior to placebo for 
efficacy (p=0·0006 for superiority; table 2 and figure 2). 
The HRs for each of the components of the composite 
were 0·93 (95% CI 0·73–1·19) for death from cardio-
vascular causes, 0·75 (0·61–0·90) for myocardial 
infarction, and 0·86 (0·66–1·14) for stroke. Prespecified 
subgroup analyses are shown in figure 3. Three of 
19 subgroups showed a nominally significant interaction 
between treatment and subgroup.
The effects of albiglutide on the other secondary 
cardiovascular outcomes were consistent with its effect on 
the primary outcome (table 2). The HR for death from any 
cause was 0·95 (95% CI 0·79–1·16). Mean glycated 
haemoglobin decreased more in patients in the albiglutide 
group than in those in the placebo group (difference from 
placebo at 8 months –0·63%, 95% CI –0·69 to –0·58; at 
16 months –0·52%, –0·58 to –0·45, figure 4). Bodyweight 
decreased more in patients in the albiglutide group than 
the placebo group (difference from placebo at 8 months 
–0·66 kg, –0·83 to –0·49; at 16 months –0·83 kg, 
–1·06 to –0·60). New treatment with insulin (taken for 
more than 3 months) was started in 107 (6%) patients in 
the albiglutide group and 257 (13%) patients in the placebo 
group (HR 0·42, 95% CI 0·33–0·53; p<0·0001). Other 
glucose-lowering therapies were added more often in the 
placebo group than in the albiglutide group (appendix 1).
Prespecified safety outcomes of special interest are 
shown in table 3. The number of injection site reactions 
was greater in the albiglutide group than in the placebo 
group (86 patients vs 29 patients), although the number of 
patients with suspected hypersensitivity reactions was 
similar between the two groups (45 patients vs 48 patients). 
Severe hypoglycaemia was less common in the albiglutide 
group than in the placebo group (31 patients vs 55 patients). 
Other than for metabolism-related events, which were less 
common in the albiglutide group, there were no clinically 
meaningful differences in serious adverse events between 
treatment groups (appendix 1). One patient in the 
albiglutide group and two patients in the placebo group 
had lower-limb amputations. 409 (9%) patients who were 
given albiglutide and 307 (6%) patients who were given 
placebo discontinued the study medication prematurely 
because of an adverse event.
Mean systolic blood pressure decreased slightly more 
in patients in the albiglutide group than in those in the 
placebo group (difference at 8 months –0·65 mm Hg, 
95% CI –1·27 to –0·03; difference at 16 months 
–0·67 mm Hg, –1·40 to 0·06; figure 4). Heart rate 
increased more in the patients in the albiglutide group 
than in those in the placebo group (1·3 beats per min, 
0·9 to 1·6; 1·4 beats per min, 1·0 to 1·9; appendix 1). The 
difference in eGFR between patients in the albiglutide 
group and those in the placebo group was –1·11 mL/min 
per 1·73 m² (95% CI –1·84 to –0·39) at 8 months and 
–0·43 per 1·73 m² (–1·26 to 0·41) at 16 months. There 
were three (<1%) deaths in the placebo group that were 
assessed by investigators, who were masked to study 
drug assignment, to be treatment-related and two (<1%) 
deaths in the albiglutide group.
Discussion
In patients with type 2 diabetes and cardiovascular 
disease who were receiving standard care, addition of 
once-weekly albiglutide reduced the risk of the primary 
composite outcome—death from cardiovascular causes, 
non-fatal myocardial infarction, or non-fatal stroke—by 
22%, compared with the addition of placebo. 50 patients 
would need to be treated with albiglutide to prevent one 
event over a median duration of 1·6 years.
Of all three components of the primary outcome, 
which were prespecified secondary outcomes, only 
myocardial infarction showed a significant point esti-
mate that indicated beneficial effect. Compared with 
trials5–8 that evaluated other GLP-1-receptor agonists, 
the effects that we observed were consistent with the 
benefits of liraglutide and semaglutide, but they appear 
greater than those of lixisenatide and exenatide. 
Whether there are real differences among the findings 
of these trials is uncertain. Several factors, including 
the specific molecule and dose tested, differences in 
the patients randomised (such as in medical history 
Albiglutide (n=4717) Placebo (n=4715) Relative risk (95% CI)
Severe hypoglycaemia 31 (1%) 55 (1%) 0·56 (0·36–0·87)
Pancreatitis* 10 (<1%) 7 (<1%) 1·43 (0·54–3·75)
Injection site reactions 86 (2%) 29 (1%) 2·96 (1·95–4·51)
Thyroid cancer 0 (0) 0 (0) ··
Haematological neoplasia 9 (<1%) 5 (<1%) 1·80 (0·60–5·36)
Pancreatic cancer 6 (<1%) 5 (<1%) 1·20 (0·37–3·93)
Hypersensitivity syndrome or 
symptoms
45 (1%) 48 (1%) 0·94 (0·63–1·40)
Hepatobiliary disorders 51 (1%) 41 (1%) 1·24 (0·83–1·87)
Alanine aminotransferase of at least 
3 times the ULN†
17 (<1%) 30 (1%) 0·57 (0·31–1·03)
Alanine aminotransferase of at least 
5 times the ULN†
6 (<1%) 17 (<1%) 0·35 (0·14–0·89)
Bilirubin of at least twice the ULN† 12 (<1%) 7 (<1%) 1·71 (0·68–4·35)
Serious gastrointestinal events 92 (2%) 87 (2%) 1·06 (0·79–1·41)
Appendicitis 3 (<1%) 8 (<1%) 0·37 (0·10–1·41)
Atrial fibrillation or flutter 108 (2%) 131 (3%) 0·82 (0·64–1·06)
Pneumonia 131 (3%) 138 (3%) 0·95 (0·75–1·20)
Renal impairment‡ 279 (6%) 319 (7%) 0·87 (0·75–1·02)
Diabetic retinopathy 78 (2%) 89 (2%) 0·88 (0·65–1·18)
Data are number of patients (%), in those who took at least one dose. Details of specified events are reported in the 
appendix. ULN=upper limit of normal. *Events prospectively adjudicated to be definite or possible pancreatitis by a 
treatment-blind adjudication committee. †Hepatic enzyme elevation was prespecified as an adverse event of special 
interest. There were four patients who had an alanine aminotransferase concentration of at least 3 times the ULN and 
a bilirubin concentration of at least twice the ULN: one patient in the albiglutide group, three patients in the placebo 
group. ‡Acute kidney injury was reported by investigators in 70 patients in the albiglutide group and 80 patients in 
the placebo group. 
Table 3: Prespecified adverse events of special interest
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and baseline characteristics), duration of follow-up, and 
adherence to treatment, could account for the apparent 
variation in results. However, this question can only be 
properly resolved by direct comparisons between 
drugs;5–8,16 a 2018 meta-analysis17 showed only moderate 
heterogeneity between the previous trials that was not 
significant.
We did not observe a significant reduction in death from 
cardiovascular causes, which was noted in the Liraglutide 
Effect and Action in Diabetes: Evaluation of Cardiovascular 
Outcome Results (LEADER) trial.5 However, we observed 
a delay between the initiation of treatment and the 
emergence of benefit, as was noted in previous trials5–8 
with GLP-1-receptor agonists, and the magnitude of the 
risk reduction for the primary outcome appeared to 
increase over time, both in our trial and the previous trials. 
The median duration of follow-up in our trial was 
considerably shorter than the 3·8 years in the LEADER 
trial, and it might be that an effect on death from 
cardiovascular causes requires additional time to accrue.
The effect of albiglutide was generally consistent across 
most subgroups analysed, although three of the 
19 subgroups examined showed some heterogeneity in 
the effect of treatment. Given the absence of a biologically 
plausible explanation for this finding and of any similar 
interactions in other trials that used GLP-1-receptor 
agonists, we believe that our subgroup findings are 
probably due to chance and are related to the large 
number of subgroups analysed.
The point estimate for another secondary outcome—
death from cardiovascular causes or hospital admission 
because of heart failure—did not significantly differ 
between the albiglutide and placebo groups. This 
finding is clinically relevant, given concerns about 
increased risk of heart failure with other glucose-
lowering therapies.18
The benefit of albiglutide was evident in patients who 
were treated with other effective cardiovascular therapies. 
Despite no major difference between the treatment 
groups in blood pressure, bodyweight, or renal function 
over time, treatment with albiglutide reduced the risk of 
major cardiovascular events over a relatively short period 
of follow-up. The mean glycated haemoglobin 
concentration at baseline was 8·7% and was reduced by 
approximately 1% after 4 months in the albiglutide group 
compared with placebo and remained lower in the 
albiglutide group for the duration of the trial, despite a 
decrease in glycated haemoglobin over time in the 
placebo group. Other glucose-lowering therapies, 
including SGLT-2 inhibitors and insulin, were added 
more commonly to the treatment regimens of patients in 
the placebo group than those in the albiglutide group. 
The exact reasons why GLP-1 receptor agonists reduce the 
incidence of atherothrombotic events is unknown; 
however, putative, potentially beneficial, cardiovascular 
actions of these drugs have been described.19 
The only prespecified adverse event of interest that was 
substantially more common in the albiglutide group was 
injection-site reactions, although this adverse event 
occurred in less than 2% of patients. Severe hypoglycaemia 
was un common overall and occurred less frequently in 
the albiglutide group than in the placebo group, probably 
due, in part, to the greater use of insulin and other 
glucose-lowering therapies in the placebo group. There 
was no excess of reported new or worsening retinopathy 
in the albiglutide group.20,21 Only serious adverse events 
(excluding outcomes) were recorded in addition to the 
prespecified adverse events of interest, and these adverse 
events did not occur at any difference in frequency 
between the albiglutide and placebo groups for non-
metabolism-related events. Overall, albiglutide treatment 
was discontinued slightly less frequently than placebo 
treatment, although it should be noted that, by design, 
our trial did not require forced up-titration of the dose of 
study drug.11
One strength of our trial was that, except for 
GLP-1-receptor agonists, investigators were free to use 
any other glucose-lowering therapy, including dipeptidyl 
peptidase 4 inhibitors and SGLT-2 inhibitors. The 
inclusion and exclusion criteria ensured a high rate of 
cardiovascular events. Our trial also has some limitations, 
including the short duration of follow-up, and absence of 
measurement of lipids and urinary albumin excretion. 
We also did not collect detailed information on 
microvascular complications. Although the short overall 
duration of follow-up might raise concerns about 
identification of longer-term safety problems, previous 
studies10 on albiglutide collected information on safety 
and tolerability for up to 3 years. About a quarter of 
patients discontinued study treatment in our trial, which 
is concordant with discontinuation rates in other trials3–8 
that used GLP-1-receptor agonists, and study treatment 
was taken for approximately 86% of the total follow-up 
time for cardiovascular outcomes
In summary, when added to standard care in patients 
with type 2 diabetes and established cardiovascular 
disease, the long-acting GLP-1-receptor agonist albiglutide 
reduced the risk of major adverse cardiovascular events 
with acceptable tolerability and safety. These findings 
provide more evidence that certain GLP-1-receptor 
agonists can improve cardiovascular outcomes in patients 
with type 2 diabetes.21–23
Contributors
AFH, SJ, RBD’A, NPJ, LAL, AER, JJVM, and SDP contributed to the 
design of the study. KNS and MCS analysed the data. AFH, JBG, SJ, 
RBD’A, CBG, NPJ, LAL, KNS, MCS, KMT, JJVM, and SDP interpreted 
the data. JJVM drafted the report, which was critically revised by AFH, 
JBG, SJ, RBD’A, CBG, NPJ, LAL, KNS, MCS, KMT, JJVM, and SDP. 
All authors have read and approved the final version.
Declaration of interests
AFH reports grants to his institution from AstraZeneca, 
GlaxoSmithKline, Luitpold Pharmaceuticals, Novartis, Merck, Portola 
Pharmaceuticals, and Verily; and he has been a consultant for 
AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Novartis, 
and Merck. JBG reports grants to her institution from AstraZeneca, 
Boehringer Ingelheim, and GlaxoSmithKline; and she has been 
Articles
www.thelancet.com   Published online October 2, 2018   http://dx.doi.org/10.1016/S0140-6736(18)32261-X 11
consultant for AstraZeneca, Boehringer Ingelheim, Novo Nordisk, 
and Merck. SJ, NPJ, and KMT are GlaxoSmithKline employees and 
shareholders. RBD’A is a consultant for GlaxoSmithKline (for the 
Harmony Outcomes trial). CBG reports grants to his institution from 
Apple, Armetheon, Daiichi Sankyo, the US Food and Drug 
Administration, and AstraZeneca; and reports consultancy fees from 
AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, 
GlaxoSmithKline, Janssen Pharmaceutica, Medtronic, the National 
Institutes of Health, Novartis, Pfizer, AbbVie, Boston Scientific, Gilead 
Sciences, Medscape, Merck, Novo Nordisk, Rho, Roche Diagnostics, 
Sirtex Medical, and Verseon. LAL reports grants to his institution from 
AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, 
GlaxoSmithKline, Janssen, Merck, Novo Nordisk, and Sanofi; he reports 
honoraria for presentation from AstraZeneca, Boehringer Ingelheim, 
Eli Lilly and Company, Janssen Pharmaceutica, Merck, Novo Nordisk, 
Sanofi, and Servier; and he reports participation on advisory boards for 
AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Janssen, 
Merck, Novo Nordisk, Sanofi, and Servier. AER reports grants to her 
institution from GlaxoSmithKline. KNS reports grants to her institution 
from GlaxoSmithKline and CSL Behring. MCS is a former employee of 
and shareholder in GlaxoSmithKline and is an employee of PAREXEL 
International. JJVM reports grants to his institution from Boehringer 
Ingelheim and Bristol-Myers Squibb, consultancy fees to his institution 
from Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Cardurion 
Pharmaceuticals, DalCor Pharmaceuticals, GlaxoSmithKline, 
Johnson & Johnson, Merck, Novartis, and Theracos, and honoraria to his 
institution for presentations from AstraZeneca, Novartis, and Pfizer. 
SDP reports grants to his institution from AstraZeneca, Boehringer 
Ingelheim, Merck, and Novartis; he reports honoraria for presentations 
from AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Merck, 
Novartis, Novo Nordisk, and Takeda Pharmaceuticals; and he reports 
participation in advisory boards for Abbott Laboratories, AstraZeneca, 
Boehringer Ingelheim, Eli Lilly and Company, GlaxoSmithKline, Merck, 
Mundipharma, Novartis Pharmaceuticals, Novo Nordisk, Sanofi, Servier, 
and Takeda Pharmaceuticals.
Data sharing
Anonymised individual participant data and study documents can be 
requested for further research from Clinical Study Data Request after 
publication of this Article.
Acknowledgments
This study was supported by GlaxoSmithKline Research & Development 
(GSK). Details of the trial organisation and a complete list of the 
investigators are provided in appendix 1. The statistical analyses were 
done by a contract research organisation on behalf of the sponsor, 
according to a prespecified plan, and corroborated by Duke Clinical 
Research Institute. The statistical analysis plan is available in appendix 1. 
We thank Yuliya Lokhnygina (Duke Clinical Research Institute) for 
statistical support and supervision; Drusilla Noronha, Rachael Russell, 
and Murray Stewart (current or former GSK employees) for their 
assistance in protocol development, trial conduct, and other scientific 
input; and the trial participants, investigators, trial site staff, and the 
employees and contractors of the sponsor who were involved in the 
conduct of the trial.
References
1 Rawshani A, Rawshani A, Franzén S, et al. Mortality and 
cardiovascular disease in type 1 and type 2 diabetes. 
N Engl J Med 2017; 376: 1407–18.
2 Rao Kondapally Seshasai S, Kaptoge S, Thompson A, et al. 
Diabetes mellitus, fasting glucose, and risk of cause-specific death. 
N Engl J Med 2011; 364: 829–41.
3 Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, 
cardiovascular outcomes, and mortality in type 2 diabetes. 
N Engl J Med 2015; 373: 2117–28.
4 Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and 
cardiovascular and renal events in type 2 diabetes. 
N Engl J Med 2017; 377: 644–57.
5 Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and 
cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 
375: 311–22.
6 Marso SP, Bain SC, Consoli A, et al. Semaglutide and 
cardiovascular outcomes in patients with type 2 diabetes. 
N Engl J Med 2016; 375: 1834–44.
7 Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with 
type 2 diabetes and acute coronary syndrome. N Engl J Med 2015; 
373: 2247–57.
8 Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly 
exenatide on cardiovascular outcomes in type 2 diabetes. 
N Engl J Med 2017; 377: 1228–39.
9 Tahrani AA, Barnett AH, Bailey CJ. Pharmacology and therapeutic 
implications of current drugs for type 2 diabetes mellitus. 
Nat Rev Endocrinol 2016; 12: 566–92.
10 Fisher M, Petrie MC, Ambery PD, Donaldson J, Ye J, McMurray JJ. 
Cardiovascular safety of albiglutide in the Harmony programme: 
a meta-analysis. Lancet Diabetes Endocrinol 2015; 3: 697–703.
11 Green JB, Hernandez AF, D’Agostino RB, et al. 
Harmony Outcomes: a randomized, double-blind, 
placebo-controlled trial of the effect of albiglutide on major 
cardiovascular events in patients with type 2 diabetes mellitus—
rationale, design, and baseline characteristics. Am Heart J 2018; 
203: 30–38.
12 Dmitrienko A, D’Agostino RB Sr. Multiplicity considerations in 
clinical trials. N Engl J Med 2018; 378: 2115–22.
13 US Department of Health and Human Services, Food and Drug 
Administration, Center for Drug Evaluation and Research. 
Guidance for industry: diabetes mellitus—evaluating cardiovascular 
risk in new antidiabetic therapies to treat type 2 diabetes. December, 
2008. https://www.fda.gov/downloads/Drugs/Guidance 
ComplianceRegulatoryInformation/Guidances/UCM071627.pdf 
(accessed Sept 22, 2018).
14 Mauri L, D’Agostino RB Sr. Noninferiority trials. N Engl J Med 2018; 
378: 304–05.
15 Cox DR. Regression models and life tables. J Royal Stat Soc 1972; 
34: 187–220.
16 Boyle JG, Livingstone R, Petrie JR. Cardiovascular benefits of 
GLP-1 agonists in type 2 diabetes: a comparative review. 
Clin Sci 2018; 132: 1699–709.
17 Bethel MA, Patel RA, Merrill P, et al. Cardiovascular outcomes with 
glucagon-like peptide-1 receptor agonists in patients with type 2 
diabetes: a meta-analysis. Lancet Diabetes Endocrinol 2018; 6: 105–13.
18 McMurray JJ, Gerstein HC, Holman RR, Pfeffer MA. Heart failure: 
a cardiovascular outcome in diabetes that can no longer be ignored. 
Lancet Diabetes Endocrinol 2014; 2: 843–51.
19 Rizzo M, Nikolic D, Patti AM, et al. GLP-1 receptor agonists and 
reduction of cardiometabolic risk: potential underlying 
mechanisms. Biochim Biophys Acta 2018; 1864: 2814–21.
20 Vilsbøll T, Bain SC, Leiter LA, et al. Semaglutide, reduction in 
glycated haemoglobin and the risk of diabetic retinopathy. 
Diabetes Obes Metab 2018; 20: 889–97.
21 Leiter LA, Nauck MA. Efficacy and safety of GLP-1 receptor agonists 
across the spectrum of type 2 diabetes mellitus. 
Exp Clin Endocrinol Diabetes 2017; 125: 419–35.
22 Abdul-Ghani M, DeFronzo RA, Del Prato S, Chilton R, Singh R, 
Ryder REJ. Cardiovascular disease and type 2 diabetes: has the 
dawn of a new era arrived? Diabetes Care 2017; 40: 813–20.
23 Lingvay I, Leiter LA. Use of GLP-1 RAs in cardiovascular disease 
prevention: a practical guide. Circulation 2018; 137: 2200–02.
For Clinical Study Data Request 
see www.clinicalstudydata 
request.com
